✦ LIBER ✦

WS7.5 Interim results of the phase 3 open-label study of ataluren in nonsense mutation cystic fibrosis (nmCF)

✍ Scribed by Kerem, E.; Wilschanski, M.; Sermet-Gaudelus, I.; De Boeck, K.; Accurso, F.J.; Konstan, M.; Rowe, S.; Miller, N.; Elfring, G.; Spiegel, R.; Peltz, S.; Barth, J.; Ajayi, T.

Book ID: 123374551
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 61 KB
Volume: 12
Category: Article
ISSN: 1569-1993
DOI: 10.1016/S1569-1993(13)60044-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

65 Phase 3 study of ataluren (PTC124®) i

65 Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data

✍ E. Kerem; M. Wilschanski; K. De Boeck; I. Sermet-Gaudelus; S. Constantine; G.L. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Ataluren for the treatment of nonsense-m

Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial

✍ Kerem, Eitan; Konstan, Michael W; De Boeck, Kris; Accurso, Frank J; Sermet-Gaude 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 336 KB

63 The use of high resolution computeriz

63 The use of high resolution computerized tomography of the chest in evaluating the effect of ataluren in nonsense mutation cystic fibrosis (nmCF) lung disease

✍ Ajayi, T.; Konstan, M.; Accurso, F.J.; De Boeck, K.; Kerem, E.; Rowe, S.; Sermet 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Phase III study of inhaled dry powder ma

Phase III study of inhaled dry powder mannitol (Bronchitol™) in cystic fibrosis – results from the 6 and 12 month open label phase

✍ D. Bilton; P. Robinson; P. Cooper; J. Kolbe; C.G. Gallagher; H. Fox; B. Charlton 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 56 KB

77* Phase III Study [CF-302] of inhaled

77* Phase III Study [CF-302] of inhaled dry powder mannitol (Bronchitol(tm)) in cystic fibrosis – results from the 6 month open label phase

✍ M. Aitken; P.A. Flume; D.E. Geller; A. Lapey; J. Zuckerman; K. De Boeck; G. Bell 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB

WS5.5 A randomised, open label phase 3 s

WS5.5 A randomised, open label phase 3 study to evaluate the efficacy and safety of a dry powder formulation of inhaled colistimethate sodium (Colobreathe®) versus tobramycin nebuliser solution (TNS) in cystic fibrosis subjects with chronic Pseudomonas aeruginosa lung infection

✍ M. Goldman; A. Schuster; C. Halliburn; G. Döring 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 61 KB